LEIFRAS Co., Ltd. Ranked No. 1 in Japan by Number of Supported School Club Activities with 2,120 Contracts

by | PRNewswire Asia

Strengthening Leadership in Facilitating Japan’s Nationwide School Club Reform and Expanding Its Role as a Sustainable Education Infrastructure Provider TOKYO, May 14, 2026 /PRNewswire/ — LEIFRAS Co., Ltd. (Nasdaq: LFS) (the "Company" or...

Modern Dairy Named "Most Honored Company" by Extel for the First Time

by | PRNewswire Asia

HONG KONG, May 14, 2026 /PRNewswire/ — On May 14, the authoritative financial magazine Extel (formerly Institutional Investor magazine) officially released the results of the "2026 Asia (ex-Japan/ANZ) Executive Team – SMID" rankings. In the...

Applications Open for Second Annual Asia-Pacific Global Health Innovation Hackathon on Maternal & Child Nutrition

by | PRNewswire Asia

12 teams, 48 Hours. Innovating for a healthier, more equitable Asia-Pacific SINGAPORE, May 14, 2026 /PRNewswire/ — Applications are now open for the second annual Asia-Pacific Global Health Innovation Hackathon, to be held in Singapore on 18–19 September 2026....

SingPost and Fullerton Health to Collaborate on Healthcare Logistics and Last-Mile Medical Delivery

by | PRNewswire Asia

SINGAPORE, May 14, 2026 /PRNewswire/ — Singapore Post Limited ("SingPost") and Fullerton Healthcare Group Private Limited ("Fullerton Health") have today announced the signing of a Memorandum of Understanding ("MOU") to explore the...

Singapore's First Immersive Installation on the Cycles of Intergenerational Harm Opens at One Punggol This May

by | PRNewswire Asia

Why Hurt Children Hurt Children invites Singaporeans to step inside The Black Box — a confrontational, compassionate experience addressing the emotional harm that passes silently from one generation to the next SINGAPORE, May 14, 2026 /PRNewswire/ —...

MEDIPOST's CARTISTEM® Meets All Primary and Secondary Endpoints in Japan Phase 3 Trial and Demonstrates Statistically Significant Efficacy Gains Versus Active Control

by | PRNewswire Asia

– Achieved statistical significance versus standard-of-care (SOC) control across all key efficacy endpoints in the 52-week study- Japan Phase 3 results strengthen CARTISTEM’s® global commercial prospects, with Japan biologics license application (BLA)...